Insulet, a developer of insulin pump technology, has announced the full availability of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the UK and the Netherlands.
The automated insulin delivery (AID) system, compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now accessible for individuals aged two years and older with type 1 diabetes.
The company has also introduced Omnipod 5 in France, specifically designed for people with type 1 diabetes aged two years and older and integrated with Dexcom G6 CGM sensors.
Insulet disclosed that Omnipod 5 has attained reimbursement status from the French National Authority for Health (Haute Autorité de Santé or HAS), ensuring accessibility for eligible individuals with type 1 diabetes.
According to the Massachusetts-based medical device company, Omnipod 5 is the first tubeless automated insulin delivery system to be integrated with both Dexcom and Abbott FreeStyle Libre CGM sensors. This system is touted as the first tubeless, waterproof AID solution featuring proactive glucose control, designed with a strong emphasis on user-friendliness.
Clinical trials conducted by Insulet have demonstrated significant clinical benefits, including lower A1c levels and increased time spent within target glucose ranges, while minimising time spent in hypoglycemia.
The flexibility of Omnipod 5 extends to its multiple sensor integrations, accommodating both Dexcom G6 and Abbott FreeStyle Libre 2 Plus sensors. This allows healthcare providers to tailor sensor recommendations based on patient preferences, simplifying the initiation of AID therapy with Omnipod 5.
Insulet senior vice president and international general manager Patrick Crannell said: “Expanding global access to Omnipod 5 is one of our top priorities.
“With the exciting, updated compatibility with both the Abbott FreeStyle Libre 2 Plus and the Dexcom G6 sensors, thousands more people with diabetes can enjoy the incredible freedom of tubeless, automated insulin delivery without having to change their CGM sensor brand.”
In the US, Insulet has commenced the full commercial launch of Omnipod 5 with integration capabilities for Dexcom G7 sensors. Omnipod 5 is claimed to be the sole tubeless AID system compatible with both Dexcom G6 and G7 sensors, providing increased options for individuals managing type 1 diabetes.
New customers adopting Omnipod 5 will receive an updated starter kit, featuring a new Pod compatible with Dexcom G6 and G7 sensors, along with a controller offering user-selectable options to connect with Dexcom CGM sensors.
Insulet anticipates rolling out a free remote software update to existing Omnipod 5 users in the U.S. by the week of 29 July 2024.
Additionally, Insulet has initiated a limited market release of the Omnipod 5 App for iPhone in the US, starting with Dexcom G6 integration. The company plans to announce the availability of the Omnipod 5 App for iPhone on the App Store, with integration for Dexcom G7 sensors slated for future release.
